





RealRate

# HEALTH SERVICES 2020

## Viridian Therapeutics Inc.\DE Rank 62 of 76



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 257% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Net Income, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is -130%, being 159% points below the market average of 29%.

Input Variable	Value in 1000 USD
Assets, Current	29,739
Assets, Non-Current	0
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	11,646
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	10,180
Long Term Liabilities	4,328
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	3.0
Other Expenses	835
Other Liabilities	0
Other Net Income	941
Other Revenues	4,461
Property Plant and Equipment	523
Research And Development Expense	34,794
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	30,262
Liabilities	14,508
Expenses	47,275
Revenues	4,461
Stockholders Equity	15,754
Net Income	-41,873
Comprehensive Net Income	-41,870
Economic Capital Ratio	-130%